Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors within the central anxious method, conolidine modulates alternate molecular targets. A Science Advances examine discovered that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://charlesk541ehh2.blogginaway.com/profile